NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	*Adherence of local formulary to NICE*				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA622 – Sotagliflozin with insulin for treating type 1 diabetes	*12th February 2020*	Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m^2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. **CCG Commissioned** **Note:** Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. Therefore the period of time the NHS has to comply with these recommendations has been extended (see the section on implementation)	*Y*		*12/05/2020*	*20/05/2020*	*98 days*
TA623 – Patiromer for treating hyperkalaemia	*13th February 2020*	Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults. **CCG Commissioned**	*Y*		*13/05/2020*	*20/05/2020*	*97 days*
TA624 – Peginterferon- beta 1a for treating relapsed-remitting multiple sclerosis	*19th February 2020*	Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults. **NHS England Commissioned**	*Y*		*20/05/2020*	*20/05/2020*	*91 days*
TA597 – Dapagliflozin with insulin for treating type 1 diabetes	*12th February 2020 updated*	Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a body mass index (BMI) of at least 27 kg/m^2. **CCG Commissioned**	*Y*		*13/05/2020*	*20/05/2020*	*98 days*
TA625 – Recombinant human parathyroid hormone for treating hypoparathyroidism	*4th March 2020 [terminated appraisal]*	NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals (now part of Takeda) did not provide an evidence submission		*N/A*	*N/A*	*N/A*	*N/A*
TA627 – Lenalidomide with rituximab for previously treated follicular lymphoma	*7th April 2020*	Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults. ***NHS England Commissioned***	*Y*		*06/07/2020*	*20/05/2020*	*43 days*
TA628 – Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer	*13th May 2020*	Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults. ***NHS England Commissioned***	*Y*		*11/08/2020*	*17/06/2020*	*35 days*
TA629 – Obinutuzumab with bendamustine for trearing follicular lymphoma after rituximab	*13th May 2020*	Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults. **Cancer Drugs Fund**	*Y*		*11/08/2020*	*17/06/2020*	*35 days*
TA630 – Larotrectinib for treating NTRK fusion-positive solid tumours	*27th May 2020*	Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children. **Cancer Drugs Fund**	*Y*		*28/08/2020*	*17/06/2020*	*21 days*
TA626 – Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	*24th June 2020*	Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure. **CCG Commissioned**	*Y*		*22/09/2020*	*15/07/2020*	*21 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA631 – Fremanezumab for preventing chronic migraine in adults	*3rd June 2020*	Evidence-based recommendations on fremanezumab (Ajovy) for preventing chronic migraine in adults. **CCG Commissioned. BlueTeq form required**	*Y*		*01/09/2020*	*15/07/2020*	*42 days*
TA632 – Trastuzumab emtansine for adjuvant treatnment of HER2-positive early breast cancer	*10th June 2020*	Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy. **NHS England Commissioned**	*Y*		*08/09/2020*	*15/07/2020*	*35 days*
TA633 – Ustekinumab for treating moderately to severe active ulcerative colitis	*17th June 2020*	Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults. **CCG Commissioned. BlueTeq form required**	*Y*		*15/09/2020*	*15/07/2020*	*28 days*
TA634 – Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma	*30th June 2020 [terminated appraisal]*	NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not provide an evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA635 – Ramucirumab with erlotinib for untreated EGFR positive metastatic non-small-cell lung cancer	*30th June 2020 [terminated appraisal]*	NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer, because Eli Lilly and Company Limited did not provide an evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA636 – Eculizumab for treating refractory myasthenia gravis.	*30th June 2020 [terminated appraisal]*	NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because Alexion Pharma UK did not provide an evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA638 – Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	*1st July 2020*	Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults. **NHS England Commissioned**	*Y*		*29/09/2020*	*19/08/2020*	*49 days*
TA639 – Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	*1st July 2020*	Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease. **NHS England Commissioned**	*Y*		*29/09/2020*	*19/08/2020*	*49 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA640 - Treosulfan with fludarabine for malignant disease before allogenic stem cell transplant	*5th August 2020*	Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable. **NHS England Commissioned**	*Y*		*03/11/2020*	*16/09/2020*	*42 days*
TA641 – Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma	*12th August 2020*	Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults. **NHS England Commissioned**	*Y*		*10/11/2020*	*16/09/2020*	*35 days*
TA642 – Gilteritinib for treating relapsed or refractory acute myeloid leukaemia	*12th August 2020*	Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults. **NHS England Commissioned**	*Y*		*10/11/2020*	*16/09/2020*	*35 days*
TA643 – Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer	*12th August 2020*	Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors. **NHS England Commissioned**	*Y*		*10/11/2020*	*16/09/2020*	*35 days*
TA644 – Entrectinib for treating neurotrophic tyrosine receptor kinase fusion-positive solid tumours in adults and children over 12 years	*12th August 2020*	Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years. Cancer Drugs Fund	*Y*		*10/11/2020*	*16/09/2020*	*35 days*
TA645 – Avelumab with axitinib for untreated advanced renal cell carcinoma	*2nd Sept 2020*	Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.	*Y*		*01/12/2020*	*21/10/2020*	*49 days*
TA646 – Glasdegib with chemotherapy for untreated acute myeloid leukaemia	*2nd Sept 2020 [terminated appraisal]*	NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA647 – Eculizumab for treating relapsing neuromyelitis optica	*2nd Sept 2020 [terminated appraisal]*	NICE is unable to make a recommendation on eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK did not provide an evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA648 – Dupilumab for treating chronic rhinosinusitis with nasal polyps	*9th Sept 2020 [terminated appraisal]*	NICE is unable to make a recommendation on dupilumab (Dupixent) for treating chronic rhinosinusitis with nasal polyps because Sanofi did not provide an evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA649 - Polatuzumabvedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma	*23rd Sept 2020*	Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant. **NHS England Commissioned**	*Y*		*22/12/2020*	*21/10/20*	*28 days*
TA650 – Pembrolizumab with axitinib for untreated advanced renal cell cancer carcinoma	*30th Sept 2020*	Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.	*Y*		*22/12/2020*	*21/10/20*	*21days*

NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA651 – Naldemedine for treating opioid-induced constipation	*30th Sept 2020*	Evidence-based recommendations on naldemedine (Rizmoic) for treating opioid-induced constipation in adults who have had laxative treatment. **CCG Commissioned**	*Y*		*29/12/2020*	*21/10/20*	*21 days*
TA652 – Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer	*7th October 2020 [terminated appraisal]*	NICE is unable to make a recommendation on alpelisib (Piqray) with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer because Novartis did not provide an evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA653 – Osimertiib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer	*14th October 2020*	Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults. **NHS England Commissioned**	*Y*		*12/01/2021*	*18/11/2020*	*35 days*
TA654 – Osimertinib for intreated EGFR mutation-positive non-small-cell lung cancer	*14th October 2020*	Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults. **NHS England Commissioned**	*Y*		*12/01/2021*	*18/11/2020*	*35 days*
TA655 – Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy	*21st October 2020*	Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy. **NHS England Commissioned**	*Y*		*19/01/2021*	*18/11/2020*	*28 days*
TA152 – Drug-eluting stents for the treatment of coronary artery disease	*18th Nov 2020 [updated]*	Evidence-based recommendations on using drug-eluting stents in adults.			*16/02/2021*	*20/01/2021*	*63 days*
TA71 – Guidance on the use of coronary stents	*18th Nov 2020 [updated]*	Evidence-based recommendations on using coronary artery stents in adults.			*16/02/2021*	*20/01/2021*	*63 days*
TA656 – Siponimod for treating secondary progressive multiple sclerosis	*18th Nov 2020*	Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults. **NHS England Commissioned**	*Y*		*16/02/2021*	*20/01/2021*	*63 days*
TA657 – Carfilzomib for previously treated multiple myeloma	*18th Nov 2020 [Updates and replaces TA457]*	Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults. **NHS England Commissioned**	*Y*		*16/02/2021*	*20/01/2021*	*63 days*
TA658 – Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma	*18th Nov 2020*	Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults. **NHS England Commissioned**	*Y*		*16/02/2021*	*20/01/2021*	*63 days*
TA659 – Galcanezumab for preventing migraine	*18th Nov 2020*	Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults. **CCG Commissioned - Blueteq form required**	*Y*		*16/02/2021*	*20/01/2021*	*63 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA660 – Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer	*25th Nov 2020*	Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. **NHS England Commissioned**	*Y*		*23/02/2021*	*20/01/2021*	*56 days*
TA661 – Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma	*25th Nov 2020*	Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more. **NHS England Commissioned**	*Y*		*23/02/2021*	*20/01/2021*	*56 days*
TA662 – Durvalumab in combination for untreated extensive-stage small-cell lung cancer	*25th Nov 2020 [terminated appraisal]*	NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission. We will review this decision if the company decides to make a submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA663 - Venetoclax with Obinutuzumab for untreated chronic lymphocytic leukaemia	*9th December 2020*	Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults. **NHS England Commissioned**	*Y*		*09/03/2021*	*20/01/2021*	*42 days*
TA664 – Liraglutide for managing overweight and obesity	*9th December 2020*	Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.			*09/03/2021*	*20/01/2021*	*42 days*
TA665 – Upadacitinib for treating severe rheumatoid arthritis	*9th December 2020*	Evidence-based recommendations on upadacitinib (Rinvoq) for severe active rheumatoid arthritis in adults. **CCG Commissioned - Blueteq form required**	*Y*		*09/03/2021*	*20/01/2021*	*42 days*
TA666 – Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma	*16th December 2020*	Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment. **NHS England Commissioned**	*Y*		*16/03/2021*	*20/01/2021*	*35 days*
TA667 – Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura	*16th December 2020*	Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg. **NHS England Commissioned**	*Y*		*16/03/2021*	*20/01/2021*	*35 days*
TA668 – Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer	*6th January 2021*	Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment. **NHS England Commissioned**	*Y*		*06/04/2021*	*17/02/2021*	*42 days*
TA669 – Trifluridine-tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies	*27th January 2021*	Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more therapies.	*Y*		*27/04/2021*	*17/02/2021*	*21 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Technology appraisal (TA) (hyperlinked)	*Date of TA Release*	*Availability of medicine for NHS patients with this medical condition, as indicated by NICE*	***Adherence of local formulary to NICE***				
			Yes	*N/A*	*Date of local decision due (90 days)*	*Date of local decision made*	*Time to implement days*
TA670 – Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor	*27th January 2021*	Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor **NHS England Commissioned**	*Y*		*27/04/2021*	*17/02/2021*	*21 days*
TA672 -Brolucizumab for treating wet age-related macular degeneration [fast track]	*3rd February 2021*	Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults. **CCG Commissioned - Blueteq form required**	*Y*		*04/05/2021*	*17/02/2021*	*14 days*
TA671 – mepolizumab for treating severe eosinophilic asthma [fast track]	*3rd February 2021*	Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults. **NHS England Commissioned**	*Y*		*04/05/2021*	*17/02/2021*	*14 days*
TA673 – Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	*17thFebruary 2021*	Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults. **Cancer Drugs Fund**	*Y*		*18/05/2021*	*17/03/21*	*28 days*
TA674 – Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable.	*17th February 2021 [terminated appraisal]*	NICE is unable to make a recommendation on pembrolizumab (Keytruda) for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable in adults. This is because Merck Sharp & Dohme did not provide a complete evidence submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA675 – Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm	*17th February 2021 [terminated appraisal]*	NICE is unable to make a recommendation on vernakalant (Brinavess) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This is because Correvio Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA676 – Filgotinib for treating moderate to severe rheumatoid arthritis	*24th February 2021*	Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults. **CCG Commissioned - Blueteq form required**	*Y*		*25/05/2021*	*17/03/2021*	*21 days*
TA677 - Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma	*24th February 2021*	Evidence-based recommendations on autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton's tyrosine kinase (BTK) inhibitor. **Cancer Drugs Fund**	*Y*		*25/05/2021*	*17/03/2021*	*21 days*
TA678 - Omalizumab for treating chronic rhinosinusitis with nasal polyps	*24th February 2021 (terminated appraisal)*	NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.		*N/A*	*N/A*	*N/A*	*N/A*
TA679 - Dapagliflozin for treating chronic heart failure with reduced ejection fraction	*24th February 2021*	Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults. **CCG Commissioned - Blueteq form required**	*Y*		*25/05/2021*	*17/03/2021*	*21 days*
TA185 - Trabectedin for the treatment of advanced soft tissue sarcoma	*Updated 24th February 2021*	Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults. **NHS England Commissioned**	*Y*		*25/05/2021*	*17/03/21*	*21 days*

NICE Technology Appraisals (medicines): Formulary Adherence 2020/2021

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS

Implementation Summary 2020 - 2021

	Total TA's	*Terminated TA's*		
Total	*49*	*12*		
	% "Yes"	*% "N/A"*		*Average implementation time (days)*
Adherence statistics for 2020 - 2021	*100*	*100*		*42*